Pecs

Respiratory Conditions

Clinical research focusing on innovative treatments for chronic rhinosinusitis and asthma, with studies evaluating new therapeutic approaches for both conditions with and without nasal polyps.

Uncontrolled Asthma Management
Nasal Polyps Treatment
Viral Lung Infections

Multiple trials investigating novel medications to improve respiratory symptoms and patient quality of life.

Cardiovascular Research

Groundbreaking studies in heart failure prevention and cardiomyopathy, exploring new therapeutic options for various cardiovascular conditions.

Heart Failure Risk Reduction
Hypertrophic Cardiomyopathy
Cardiovascular Disease Prevention

Advanced research aimed at reducing cardiovascular events and improving patient outcomes.

Autoimmune Disorders

Innovative research into treatments for systemic sclerosis and Sjögren’s syndrome, focusing on novel therapeutic approaches for these challenging conditions.

Systemic Sclerosis Management
Primary Sjögren’s Disease
Autoimmune Manifestations

Studies evaluating new biological treatments to address various autoimmune conditions.

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Recruiting

1 1
Investigated drugs:
+5
Study on the Effectiveness and Safety of Oxymetazoline Hydrochloride Eye Drops for Adults with Acquired Blepharoptosis

Recruiting

1 1
Investigated drugs:
- Oxymetazoline Hydrochloride
+2
Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Recruiting

1 1
Investigated diseases:
- Acute myocardial infarction
Investigated drugs:
- Selatogrel
+17
Study on Long-Term Safety of KarXT (Trospium Chloride, Xanomeline Tartrate) for Patients with Alzheimer’s-Related Psychosis

Recruiting

1 1 1
Investigated diseases:
- Dementia Alzheimer’s type
Investigated drugs:
- Trospium Chloride
- Xanomeline Tartrate
+8
Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Recruiting

1 1 1
Investigated diseases:
- Non-small cell lung cancer
Investigated drugs:
- Mrna-4157
- Pembrolizumab
+12
Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Recruiting

1 1
Investigated drugs:
- Finerenone
+11

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Pembrolizumab Dexamethasone Carboplatin Cisplatin Prednisone Aflibercept Mycophenolate Mofetil Paclitaxel Salbutamol Inclisiran Cetuximab Vincristine Sulfate Fluorouracil Oxaliplatin Etoposide Glycopyrronium Bromide Budesonide Infliximab Finerenone Prednisolone Rituximab Salbutamol Sulfate Pemetrexed Methotrexate Formoterol Fumarate Dihydrate Triamcinolone Acetonide Ranibizumab Sodium Chloride Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues Ifosfamide Show more

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

Acromegaly Acute coronary syndrome Acute kidney injury Acute lymphocytic leukaemia Acute myeloid leukaemia Acute myocardial infarction Acute respiratory failure Age-related macular degeneration Alopecia areata Anaemia of chronic disease Analgesic therapy Anti-neutrophil cytoplasmic antibody positive vasculitis Arteriosclerosis Asthma Atrial fibrillation Atypical teratoid/rhabdoid tumour of CNS Axial spondyloarthritis B-cell small lymphocytic lymphoma B-cell type acute leukaemia Bladder cancer Bladder cancer stage II Bladder cancer stage III Breast cancer Bronchiectasis Cardiac ablation Cardiac failure Cardiac failure acute Cardiac failure chronic Cardiovascular disorder Central nervous system melanoma Cerebrovascular accident prophylaxis Chorioretinitis Chronic cutaneous lupus erythematosus Chronic inflammatory demyelinating polyradiculoneuropathy Chronic kidney disease Chronic kidney disease-associated pruritus Chronic lymphocytic leukaemia Chronic obstructive pulmonary disease Chronic rhinosinusitis with nasal polyps Chronic sinusitis Chronic spontaneous urticaria Clostridium difficile infection Coagulation factor X level Colitis ulcerative Colorectal cancer Colorectal cancer metastatic Colorectal cancer stage IV Connective tissue disorder Coronary artery disease Cough Crohn's disease Cutaneous lupus erythematosus Deep vein thrombosis Dementia Alzheimer's type Dementia of the Alzheimer's type with delusions Dermatitis Dermatitis atopic Dermatomyositis Diabetic retinal oedema Diabetic retinopathy Diffuse large B-cell lymphoma Dilated cardiomyopathy Dry age-related macular degeneration Dyslipidaemia Embolism venous Endocrine ophthalmopathy Ewing's sarcoma Eyelid ptosis Follicular lymphoma Gastric cancer Gastrointestinal cancer metastatic Gastrointestinal melanoma Glycogen storage disease type II Haematological malignancy Hepatic cirrhosis Hepatic encephalopathy Hidradenitis Hormone receptor positive breast cancer Hormone receptor positive HER2 negative breast cancer Hormone-refractory prostate cancer Hypercholesterolaemia Hypertension Hypertriglyceridaemia Hypertrophic cardiomyopathy Hypoparathyroidism IgA nephropathy Immune thrombocytopenia Immunoglobulin G4 related disease Ischaemic stroke Juvenile idiopathic arthritis K-ras gene mutation Kidney transplant rejection Left ventricular failure Lennox-Gastaut syndrome Lung disorder Lupus nephritis Macular oedema Magnetic resonance imaging Major depression Malignant melanoma Malignant melanoma of eyelid Malignant melanoma stage III Malignant melanoma stage IV Melanoma recurrent Metastatic malignant melanoma Microsatellite instability cancer Multiple sclerosis Multiple sclerosis relapse Myocardial infarction Myopia Neoplasm Neoplasm malignant Neovascular age-related macular degeneration Nephroblastoma Nephropathy Nervous system disorder Neurodermatitis Neuropathy peripheral Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Non-small cell lung cancer Non-small cell lung cancer metastatic Non-small cell lung cancer stage I Non-small cell lung cancer stage II Non-small cell lung cancer stage III Non-small cell lung cancer stage IIIB Non-small cell lung cancer stage IV Obesity Oesophageal cancer metastatic Oesophageal carcinoma Orthostatic hypotension Ovarian epithelial cancer Overweight Pain Paranasal sinus inflammation Parkinson's disease Partial seizures Pemphigoid Philadelphia positive acute lymphocytic leukaemia Pituitary-dependent Cushing's syndrome Plasma cell myeloma Plasma cell myeloma recurrent Polymyositis Postoperative analgesia Procedural pain Progressive relapsing multiple sclerosis Progressive supranuclear palsy Prostate cancer metastatic Proteinuria Psoriasis Psychotic disorder Pulmonary arterial hypertension Pulmonary hypertension Pyoderma gangrenosum Relapsing multiple sclerosis Retinal vein occlusion Secondary progressive multiple sclerosis Severe myoclonic epilepsy of infancy Sinusitis noninfective Sjogren's syndrome Skin squamous cell carcinoma metastatic Skin squamous cell carcinoma recurrent Skin ulcer Small cell lung cancer extensive stage Squamous cell carcinoma Squamous cell carcinoma of head and neck Squamous cell carcinoma of lung Squamous cell carcinoma of skin Subacute cutaneous lupus erythematosus Systemic lupus erythematosus Systemic scleroderma Systemic sclerosis pulmonary Thrombolysis Thrombosis prophylaxis Transient ischaemic attack Type 2 diabetes mellitus Type IIa hyperlipidaemia Uveitis Vitiligo

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes